ReviewTropical diseases, travel medicine and vaccines2026
The global outbreak of Oropouche virus: surveillance of global trends.
Review in Tropical diseases, travel medicine and vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Internists facing emerging arboviral diseases: time to get prepared.Internal and emergency medicine · 2026Review
- Oropouche Virus: Comparative Study of Two Strains Reveals Distinct Innate Immunity Modulation.Viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oropouche virus (OROV) is a re-emerging arthropod-borne virus of the genus Orthobunyavirus (family Peribunyaviridae) that poses an increasing public health concern in South and Central America and the Caribbean. First identified in Trinidad in 1955, OROV has caused recurrent outbreaks, with recent resurgence associated with geographic expansion and increased urban transmission. In 2024 alone, more than 11,600 confirmed cases were reported in the Region of the Americas, with continued transmission documented in early 2025. The virus is primarily transmitted in urban settings by the biting midge Culicoides paraensis, while other mosquito species have demonstrated variable laboratory vector competence. Clinically, OROV infection presents as an acute febrile illness resembling dengue, chikungunya, and other arboviral infections, frequently complicating diagnosis in co-endemic areas. Although molecular diagnostics such as RT-PCR enable early detection, standardized diagnostic protocols and validated commercial assays remain limited. No specific antiviral therapy or licensed vaccine is currently available, and prevention relies on vector control and personal protective measures. Emerging evidence has raised concern regarding potential vertical transmission of OROV during pregnancy. Case reports and recent genomic analyses have described associations between maternal infection and adverse fetal outcomes, including stillbirth, congenital microcephaly, and structural anomalies. Detection of viral RNA in placental or fetal tissues supports biological plausibility; however, systematic cohort-based epidemiological data remain limited. At present, causality cannot be definitively established, and further prospective surveillance studies are urgently needed to clarify risk magnitude and pathogenic mechanisms. This review synthesizes current knowledge on the epidemiology, virology, transmission dynamics, clinical manifestations, diagnostics, and prevention strategies of OROV and identifies key research priorities to strengthen surveillance, preparedness, and outbreak response in affected and at-risk regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.